DAT-2000 / Danatlas - LARVOL DELTA

Identification of DAT-2000A, a novel potent PARG inhibitor that selectively inhibits PARPi-resistant and homologous-recombination-deficient tumors (AACR 2024) - "Furthermore, it induces a dose and time-dependent accumulation of PAR chains, which may serve as a reliable pharmacodynamic biomarker indicative of PARG target engagement. In conclusion, DAT-2000A represents an innovative targeted therapy that warrants further investigation in clinical trials for the treatment of HRD cancers and beyond."

Breast Cancer • Oncology • Solid Tumor • HRD